Nasdaq · CIK 0001888886
GPCR Structure Therapeutics Inc.
Insider trading from SEC Form 4. Last filing 20 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Structure Therapeutics Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 36 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Crespo Blas Coll CHIEF MEDICAL OFFICER | FTax withholding Ordinary Shares10b5-1 | -10,626 | $11.67 | $124k | 270,252 | 20 d ago |
| Sep 21, 2026 | Crespo Blas Coll CHIEF MEDICAL OFFICER | CConversion Ordinary Shares10b5-1 | -12,024 | $0.00 | $0 | 258,228 | 20 d ago |
| Sep 21, 2026 | Crespo Blas Coll CHIEF MEDICAL OFFICER | CConversion American Depositary Sharesderivative10b5-1 | +4,008 | $0.00 | $0 | 5,165 | 20 d ago |
| Sep 21, 2026 | Crespo Blas Coll CHIEF MEDICAL OFFICER | SOpen-market sale American Depositary Sharesderivative10b5-1 | -4,008 | $36.15 | $145k | 1,157 | 20 d ago |
| Sep 1, 2026 | Xichen Lin CHIEF SCIENTIFIC OFFICER | MOption exercise Ordinary Shares10b5-1 | +17,817 | $0.34 | $6,058 | 246,777 | 40 d ago |
| Sep 1, 2026 | Xichen Lin CHIEF SCIENTIFIC OFFICER | CConversion Ordinary Shares10b5-1 | -17,817 | $0.00 | $0 | 228,960 | 40 d ago |
| Sep 1, 2026 | Xichen Lin CHIEF SCIENTIFIC OFFICER | MOption exercise Share Option (right to buy)derivative10b5-1 | -17,817 | $0.00 | $0 | 125,081 | 40 d ago |
| Sep 1, 2026 | Xichen Lin CHIEF SCIENTIFIC OFFICER | CConversion American Depositary Sharesderivative10b5-1 | +5,939 | $0.00 | $0 | 5,939 | 40 d ago |
| Sep 1, 2026 | Xichen Lin CHIEF SCIENTIFIC OFFICER | SOpen-market sale American Depositary Sharesderivative10b5-1 | -1,300 | $45.86 | $60k | 4,639 | 40 d ago |
| Sep 1, 2026 | Xichen Lin CHIEF SCIENTIFIC OFFICER | SOpen-market sale American Depositary Sharesderivative10b5-1 | -4,539 | $47.20 | $214k | 100 | 40 d ago |
| Sep 1, 2026 | Xichen Lin CHIEF SCIENTIFIC OFFICER | SOpen-market sale American Depositary Sharesderivative10b5-1 | -100 | $47.83 | $4,783 | 0 | 40 d ago |
| Sep 18, 2025 | Crespo Blas Coll CHIEF MEDICAL OFFICER | FTax withholding Ordinary Shares | -8,106 | $7.74 | $63k | 216,807 | Sep 22, 2025 |
| Sep 18, 2025 | Ashley Hall Chief Development Officer | FTax withholding Ordinary Shares | -6,021 | $7.74 | $47k | 112,317 | Sep 22, 2025 |
| Jul 1, 2025 | Xichen Lin CHIEF SCIENTIFIC OFFICER | FTax withholding Ordinary Shares | -12,846 | $6.84 | $88k | 204,327 | Aug 20, 2025 |
| Jul 1, 2025 | Yingli Ma CHIEF TECHNOLOGY OFFICER | FTax withholding Ordinary Shares | -4,470 | $6.84 | $31k | 118,704 | Aug 20, 2025 |
| Jul 30, 2025 | Fmr LLC owner, other | SOpen-market sale American Depositary Sharesderivativeindirect: Shares held by persons and entities whose shares are subject to reporting by the undersigned | -26,310 | $17.87 | $470k | 1,515,558 | Aug 1, 2025 |
| Mar 1, 2025 | Yingli Ma CHIEF TECHNOLOGY OFFICER | FTax withholding Ordinary Shares | -1,824 | $7.92 | $14k | 98,715 | Jul 3, 2025 |
| Mar 1, 2025 | Xichen Lin CHIEF SCIENTIFIC OFFICER | FTax withholding Ordinary Shares | -6,441 | $7.92 | $51k | 160,095 | Jul 3, 2025 |
| Mar 1, 2025 | Crespo Blas Coll CHIEF MEDICAL OFFICER | FTax withholding Ordinary Shares | -1,233 | $7.92 | $9,761 | 218,355 | Jul 3, 2025 |
| Jul 1, 2025 | Yingli Ma CHIEF TECHNOLOGY OFFICER | AGrant or award Ordinary Shares | +24,459 | $0.00 | $0 | 123,174 | Jul 3, 2025 |
| Jul 1, 2025 | Xichen Lin CHIEF SCIENTIFIC OFFICER | AGrant or award Ordinary Shares | +57,078 | $0.00 | $0 | 217,173 | Jul 3, 2025 |
| Jul 1, 2025 | Crespo Blas Coll CHIEF MEDICAL OFFICER | AGrant or award Ordinary Shares | +7,992 | $0.00 | $0 | 226,347 | Jul 3, 2025 |
| Jul 1, 2025 | Crespo Blas Coll CHIEF MEDICAL OFFICER | FTax withholding Ordinary Shares | -1,434 | $6.84 | $9,804 | 224,913 | Jul 3, 2025 |
| May 21, 2025 | Crespo Blas Coll CHIEF MEDICAL OFFICER | AGrant or award American Depositary Sharesderivative | +429 | $0.00 | $0 | 1,157 | Jul 3, 2025 |
| Jun 23, 2025 | Eric Dobmeier director | AGrant or award Share Option (right to buy)derivative | +51,804 | $0.00 | $0 | 51,804 | Jun 25, 2025 |
| Jun 23, 2025 | Ted W Love director | AGrant or award Share Option (right to buy)derivative | +51,804 | $0.00 | $0 | 51,804 | Jun 25, 2025 |
| Jun 23, 2025 | Angus C. Russell director | AGrant or award Share Option (right to buy)derivative | +42,833 | $0.00 | $0 | 42,833 | Jun 25, 2025 |
| Jun 23, 2025 | Daniel G Welch director | AGrant or award Share Option (right to buy)derivative | +51,804 | $0.00 | $0 | 51,804 | Jun 25, 2025 |
| Jun 23, 2025 | Sharon Tetlow director | AGrant or award Share Option (right to buy)derivative | +51,804 | $0.00 | $0 | 51,804 | Jun 25, 2025 |
| Jun 23, 2025 | Joanne Waldstreicher director | AGrant or award Share Option (right to buy)derivative | +51,804 | $0.00 | $0 | 51,804 | Jun 25, 2025 |
| Mar 15, 2025 | Crespo Blas Coll Chief Medical Officer | AGrant or award Ordinary Shares | +116,988 | $0.00 | $0 | 219,588 | Mar 18, 2025 |
| Mar 15, 2025 | Ashley Hall Chief Development Officer | AGrant or award Ordinary Shares | +51,048 | $0.00 | $0 | 118,338 | Mar 18, 2025 |
| Mar 15, 2025 | Crespo Blas Coll Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +284,241 | $0.00 | $0 | 284,241 | Mar 18, 2025 |
| Mar 15, 2025 | Ashley Hall Chief Development Officer | AGrant or award Employee Stock Option (right to buy)derivative | +124,032 | $0.00 | $0 | 124,032 | Mar 18, 2025 |
| Nov 20, 2024 | Crespo Blas Coll Chief Medical Officer | AGrant or award American Depositary Sharesderivative | +363 | $0.00 | $0 | 728 | Mar 18, 2025 |
| Feb 6, 2025 | Fmr LLC owner, other | SOpen-market sale American Depositary Sharesderivativeindirect: FIMM, LLC | -41 | $30.54 | $1,252 | 0 | Feb 10, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Crespo Blas CollCHIEF MEDICAL OFFICER
- Eric Dobmeierdirector
- Fmr LLCowner, other
- Ashley HallChief Development Officer
- Ted W Lovedirector
- Xichen LinCHIEF SCIENTIFIC OFFICER
- Yingli MaCHIEF TECHNOLOGY OFFICER
- Angus C. Russelldirector
- Sharon Tetlowdirector
- Daniel G Welchdirector
- Joanne Waldstreicherdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.